J Clin Oncol 2021 Aug 2
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Related Questions
Does reducing the rate of infusion, or adding Montelukast reduce chances of future reactions?
New answer by Medical Oncologist at Georgetown University Hospital (January 28, 2024)
Fortunately, G3+ infusion reactions with amivantamab are uncommon. In the CHYSALIS phase I study which led to approval for EGFR exon 20 (Park et al., PMID 34339292), G3+ infus...
New answer by Medical Oncologist at University Of Texas Southwestern Medical Center At Dallas (October 15, 2025)
For metastatic lung adenocarcinoma with an EGFR exon 20 insertion, targeted therapy is prioritized before immunotherapy. First-line treatment typically involves the targeted a...